Zinc Thymulin

Thymulin is a thymic nonapeptide that is biologically inert until it binds zinc, at which point it takes on its active conformation and regulates T-cell differentiation. Its relevance to hair came from observations that it influences the hair follicle cycle, an immune-privileged structure whose transition from anagen into catagen is partly immunologically driven. Applied topically to the scalp in androgenetic alopecia, it appears to prolong anagen and reduce shedding rather than reverse miniaturisation the way an androgen-pathway drug does. The molecular target in the follicle has not been mapped, which is the honest limit of what is known — this is an empirical observation with a plausible immunological framing, not a worked-out mechanism.

Targets: Zinc-dependent thymulin conformation, Hair follicle anagen phase, Follicular immune signalling

• · The pilot study formulation delivered roughly 100-200 mcg of peptide per application in an aqueous scalp vehicle with a zinc source. Zinc must be present in the formula or the peptide is inactive.

Work out your exact syringe units →

• rareScalp irritation— The published pilot reported no redness, no irritation and no change in hair colour or quality.

• synergyminoxidil — Different mechanisms; commonly layered, though no combination data exist.
• synergyahk-cu — Both are used in scalp serums for different parts of the follicle cycle.

• · Standardised scalp photographs and a fixed-area hair count at 0, 3 and 6 months.
• · A 60-second hair pull or wash count to track shedding, which changes before density does.

Not an approved drug. Available as a compounded or research topical; thymulin is not a standard cosmetic INCI ingredient.

• Vickers 2017, safety and efficacy of topical zinc-thymulin in androgenetic alopecia (trial)

Thymulin's established biology is immunological and has nothing to do with hair, which is worth stating clearly before anything else. It is a thymic epithelial nonapeptide, biologically inert until zinc binds and induces the active conformation — Dardenne demonstrated that with a monoclonal antibody whose epitope only exists in the zinc-bound form, and Prasad showed that serum thymulin activity falls in human zinc deficiency and is restored by repletion. Coto showed IL-1 regulates its secretion. That is a solid, decades-old literature about T-cell differentiation. The hair connection is empirical and the mechanism is genuinely not worked out, which the site should say rather than dress up. The plausible framing is immunological. The hair follicle is one of the few immune-privileged sites in the body — the anagen bulb downregulates MHC class I and maintains local immunosuppression, and loss of that privilege is what causes alopecia areata. The anagen-to-catagen transition is partly driven by immune and inflammatory signalling, and perifollicular micro-inflammation is a recognised feature of androgenetic alopecia. So a thymic immunoregulatory peptide prolonging anagen is not absurd. But no receptor has been identified in the follicle, no signalling pathway has been mapped, and the whole hair application rests on one small open-label study that I was unable to locate in PubMed or Europe PMC. That last point matters and I am flagging it rather than burying it.

Reconstituting into plain water with no zinc. The peptide is inert without it and the solution looks identical, so you get six months of nothing with no way to know why. Second, expecting density change on a shedding-reduction mechanism: reduced shedding shows up at two to three months, but reduced shedding and increased density are different endpoints and the published pilot reported vellus and intermediate hair counts rather than terminal hair, which is a much less impressive outcome than it sounds. Vellus hairs are the fine short ones; a 32% increase in vellus count is not a 32% increase in visible hair. Third, sourcing: thymulin is not a standard cosmetic INCI ingredient and is sold as a research chemical with no assay standards.

• Zinc-dependent thymulin conformation — Zinc binding is obligate for activity; the specific affinity is characterised in the immunological literature

  Without zinc the peptide is inert. This is the single most practically important fact about formulating it.

• Hair follicle anagen-to-catagen transition — No receptor identified

  Claimed prolongation of anagen and reduced shedding. Mechanism unmapped.

Month 2-3: reduced shedding, which is the earliest thing that changes on any hair intervention and the easiest to measure with wash counts. Month 6: the endpoint of the published pilot, and the earliest point at which fixed-area counts are meaningful. Anything assessed before three months is noise, because the hair cycle does not move faster than that.

Zinc is not a stacking partner, it is a component — a formulation without a soluble zinc source gives you inactive apo-thymulin, and this is the single most common way people waste this compound. Minoxidil works through a completely different mechanism (potassium channel opening, vasodilation, sulfotransferase-dependent activation) so there is no overlap and no interaction data. Layering both is common practice and unstudied. The genuinely important co-intervention is checking and correcting ferritin, serum zinc and thyroid function before you start, because those three account for a large fraction of shedding that gets misattributed to androgenetic alopecia and none of them respond to a peptide. And if the problem is androgen-driven miniaturisation, an anti-androgen does something this peptide does not — thymulin appears to prolong anagen rather than reverse miniaturisation, which are different outcomes.

Against minoxidil and finasteride, no contest on evidence — those have large randomised trials and this has one small open-label pilot I could not locate in the literature databases. Against the other experimental hair peptides in this class, zinc thymulin is unusual in that it has apparently been applied to human scalps in a study at all, which puts it ahead of PTD-DBM and topical thymosin beta-4 on that narrow criterion. Against AHK-Cu and biotinoyl tripeptide-1, all three are scalp-serum ingredients with thin evidence, and none of them addresses the androgen pathway that actually drives androgenetic alopecia.

$40–$150/month. Sold as a research chemical at roughly $40-100 per 5-10 mg vial, with community protocols using 100-200 mcg per application. Compounded scalp preparations vary widely. Market observation, not a sourced pricing study.

• ?I could not locate the cited zinc-thymulin androgenetic alopecia pilot study in PubMed or Europe PMC in this session. The 18-subject, six-month, 32% vellus and 23% intermediate hair count figures in the Core record should be treated as unverified until someone resolves the primary source. It may exist as a conference abstract or in a non-indexed journal.
• ?The nonapeptide sequence of thymulin is published in the immunological literature but I did not resolve it in this session.
• ?The molecular weight of 857.9 Da in the Core record is unconfirmed against a primary source.
• ?No receptor or signalling pathway for thymulin in the hair follicle has been identified.
• ?No permeation data exist for scalp application, and the follicular delivery route is a reasonable hypothesis rather than a demonstrated one.
• ?Whether the vellus and intermediate hair count increases reported translate into visible cosmetic benefit is doubtful and untested.

• A zinc-dependent epitope on the molecule of thymulin, a thymic hormone Dardenne M, et al., Proceedings of the National Academy of Sciences USA, 1985 · PMID 2413455

  The primary demonstration that zinc binding creates the active conformation. This is why zinc is not optional in the formulation.

• The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin Reggiani PC, et al., Annals of the New York Academy of Sciences, 2009 · PMID 19236333

  The best modern overview of thymulin biology, and the source confirming it is a nonapeptide coupled to zinc which confers biological activity.

• Serum thymulin in human zinc deficiency Prasad AS, Meftah S, Abdallah J, et al., Journal of Clinical Investigation, 1988 · PMID 3262625

  Establishes the zinc-thymulin relationship in humans directly, and why serum zinc is worth checking in anyone with shedding.

• Interleukin 1 regulates secretion of zinc-thymulin by human thymic epithelial cells and its action on T-lymphocyte proliferation and nuclear protein kinase C Coto JA, et al., Proceedings of the National Academy of Sciences USA, 1992 · PMID 1502195

  Shows the inflammatory regulation of zinc-thymulin, which is the closest thing to a mechanistic bridge toward the follicular immune-privilege argument.

• Overview of Short Peptides for Hair Loss Fan C, Chen Y, Huang Q, Ou WY, Zhang C, Sun Y, Wu T, Leung OY, Iu HC, Shi J, Biomedicines, 2026 · PMID 42072405

  Recent review of the peptide hair-loss field for context.